Tiger Brokers

HK StockDetailed Quotes
Provided by Tiger Fintech (Singapore) Pte. Ltd.

HAIXI PHARMA

141.100
-3.100-2.15%
Volume:66.10K
Turnover:9.37M
Market Cap:11.11B
PE:- -
High:146.200
Open:144.400
Low:139.000
Close:144.200
52wk High:147.000
52wk Low:97.500
Shares:78.71M
HK Float Shares:78.71M
Volume Ratio:0.53
T/O Rate:0.08%
Dividend:- -
Dividend Rate:- -
ROE:28.75%
ROA:12.62%
PB:18.74
PE(LYR):- -
PS:21.74

Loading ...

OverviewCompanyNewsFilings

Company Profile

Company Name:
HAIXI PHARMA
Exchange:
SEHK
Establishment Date:
2012
Employees:
164
Office Location:
Floor 3 & 4, Block B,No. 177 Jinda Road,Jianxin Town,Cangshan District,Fuzhou,Fujian Province,China
Website:
http://www.hxpharma.com
Zip Code:
350028
Phone:
86 591 8751 9936
Fax:
- -
Introduction:
Fujian Haixi Innovative Drug Development Co., Ltd. was established on March 27, 2012. The company is a commercial-stage pharmaceutical firm that integrates R&D, manufacturing and sales capabilities, and maintains a pipeline of innovative drug candidates. It owns a diversified product portfolio and pipeline across China’s largest and fastest-growing therapeutic areas. As of the latest practicable date, its commercialized portfolio consists mainly of generics for digestive, cardiovascular, endocrine, neurological and inflammatory diseases. According to CIC, these therapeutic areas accounted for over 25 % of China’s total pharmaceutical sales in 2023. The company’s innovative pipeline focuses on drug candidates for multiple indications, including a potential first-in-class oncology asset, a potential first-in-class oral therapy for wet age-related macular degeneration (wAMD) / diabetic macular edema (DME) / retinal vein occlusion (RVO), and two additional pre-clinical-stage innovative programs for oncology and respiratory diseases. All innovative drug candidates are developed and advanced internally through proprietary technologies.

Directors

Name
Position
KANG Xin Shan
Chairman of the Board,Executive Director,Chairman of the Strategic and Development Committee,Member of the Remuneration and Assessment Committee,Chairman of the Nomination Committee
Feng Yan
Executive Director,Member of the Strategic and Development Committee
Chen Guangming
Executive Director
CHEN Shu Yi
Executive Director,Advisor
GONG Wei Min
Independent Director,Member of the Strategic and Development Committee,Chairman of the Remuneration and Assessment Committee,Audit Committee Member
WANG Shan Shan
Independent Director,Member of the Nomination Committee,Audit Committee Member
PU Mei Ting
Independent Director,Member of the Remuneration and Assessment Committee,Member of the Nomination Committee,Audit Committee Chairman
XU Dong
Director
WANG Xin Kun
Director
CHEN Xia
Supervisor,Employee Supervisor
WU Jiang
Supervisory
XU Li Xia
Supervisory

Shareholders

Name
Position
KANG Xin Shan
General Manager
Feng Yan
Vice General Manager
Chen Guangming
Vice General Manager,Chief Science Officer
HU Kai
Vice General Manager,Assistant to the General Manager
ZHANG Juan Huan
CFO,Board Secretary,Corporate Secretary
CHEN Xiao Lin
Corporate Secretary
CHEN Xia
Other Senior Executives,Other Senior Executives